F

Fortrea Holdings Inc
NASDAQ:FTRE

Watchlist Manager
Fortrea Holdings Inc
NASDAQ:FTRE
Watchlist
Price: 19.73 USD 1.18% Market Closed
Market Cap: 1.8B USD
Have any thoughts about
Fortrea Holdings Inc?
Write Note

Fortrea Holdings Inc
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Fortrea Holdings Inc
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
F
Fortrea Holdings Inc
NASDAQ:FTRE
Cost of Revenue
-$2.6B
CAGR 3-Years
-7%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Cost of Revenue
-$25.1B
CAGR 3-Years
-9%
CAGR 5-Years
-12%
CAGR 10-Years
-11%
Danaher Corp
NYSE:DHR
Cost of Revenue
-$8.6B
CAGR 3-Years
8%
CAGR 5-Years
-4%
CAGR 10-Years
0%
Mettler-Toledo International Inc
NYSE:MTD
Cost of Revenue
-$1.5B
CAGR 3-Years
-1%
CAGR 5-Years
-4%
CAGR 10-Years
-3%
Agilent Technologies Inc
NYSE:A
Cost of Revenue
-$2.9B
CAGR 3-Years
-1%
CAGR 5-Years
-5%
CAGR 10-Years
-11%
IQVIA Holdings Inc
NYSE:IQV
Cost of Revenue
-$9.9B
CAGR 3-Years
-3%
CAGR 5-Years
-7%
CAGR 10-Years
-10%
No Stocks Found

Fortrea Holdings Inc
Glance View

Market Cap
1.8B USD
Industry
Life Sciences Tools & Services

Fortrea Holdings, Inc. engages in the provision of clinical development and commercialization services. The company is headquartered in Durham, North Carolina and currently employs 19,000 full-time employees. The company went IPO on 2023-06-16. The firm is a provider of comprehensive Phase I through IV clinical trial management, clinical pharmacology, patient access solutions and other enabling services. The Company’s segments include Clinical Services and Enabling Services. The Company’s global solutions include Clinical Development, Clinical Pharmacology, Drug Development Consulting Services, Device and Diagnostic Development, and Full and Functional Service Provider Models, among others. Its Clinical Development solutions include Early: Phase I/II a, Late: Phase II b/III, Real-World Evidence and Post-Approval Studies, Decentralized Clinical Trials, Data Analysis and Reporting, Clinical Trial Project Management and Monitoring, and Patient Safety and Pharmacovigilance. By therapeutic or specialty areas, it has scientific expertise in cardiovascular, cell and gene therapies, dermatology, diabetes and endocrinology, hepatology, infectious disease, and others.

FTRE Intrinsic Value
31.53 USD
Undervaluation 37%
Intrinsic Value
Price
F

See Also

What is Fortrea Holdings Inc's Cost of Revenue?
Cost of Revenue
-2.6B USD

Based on the financial report for Dec 31, 2023, Fortrea Holdings Inc's Cost of Revenue amounts to -2.6B USD.

What is Fortrea Holdings Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 3Y
-7%

Over the last year, the Cost of Revenue growth was -6%. The average annual Cost of Revenue growth rates for Fortrea Holdings Inc have been -7% over the past three years .

Back to Top